Dr Reddy’s Laboratories ( (RDY) ) has provided an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Dr. Reddy’s Laboratories has approved the allotment of 13,080 equity shares to employees under its Employees Stock Options Scheme, 2002, as part of its commitment to rewarding and retaining talent. This move reflects the company’s strategic approach to employee compensation and its continuous efforts to align employee interests with its business objectives, potentially enhancing stakeholder value.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in Hyderabad, India, primarily engaged in the development and marketing of a wide range of pharmaceutical products. The company operates in the generic medicine sector and is listed on major stock exchanges including the National Stock Exchange of India, BSE, and the New York Stock Exchange.
YTD Price Performance: 9.17%
Average Trading Volume: 1,032,411
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $13B
See more data about RDY stock on TipRanks’ Stock Analysis page.
